$ASTI Solar Technology - The power density of WaveSol™ Mobile technology makes it the preferred solution!

$ASTI - HOW ASCENT'S SOLAR TECHNOLOGY WORKS 

Ascent Solar’s WaveSol™ Mobile, flexible, thin-film modules for EIPV are specifically produced for integrating solar power into electronic devices and consumer products. WaveSol™ Light modules are manufactured on ultra-thin plastic substrates, which provide the flexibility necessary for easy integration to all types of materials including fabrics and plastics. Ascent Solar’s CIGS technology offers the greatest power per space compared to other available technologies, making solar-powered consumer products a reality.

1. Highest energy density available on thin-film PVs
2. Manufactured on plastic
3. Requires fewer balance of system components
4. Lightweight form factor
5. Flexibility provides the opportunity to solar power a multitude of
6. consumer products.
7. A realistic source of clean, renewable energy

The lightweight, yet powerful Ascent Solar WaveSol™ Mobile modules make it easy to directly integrate solar power into a limitless number of consumer products that benefit from portable power, including fabrics and non-flat surfaces. The power density of the thin-film, CIGS technology makes it the preferred solution for meeting the energy needs of solar-powered consumer products such as laptop computers, tents, off-grid LED lighting, blankets and more.

• Most Powerful
  WaveSol™ Mobile modules offer the greatest power density compared to other available technologies. The power these modules produce can replace heavy, traditional batteries, eliminate the need for extra power boosters and bring the advantage of solar power to new consumer products.

• Maximum Portability
  WaveSol™ Mobile modules are created on plastic, not glass, which makes them significantly lighter and more durable. The flexibility of the plastic substrate allows for solar panels to be sewn into fabric or placed in areas previously unavailable for solar energy production.

• Clean, Alternative Energy Source
  WaveSol™ Mobile modules harness the power of the sun to provide an alternative energy source that reduces the use of chemicals found in traditional batteries.

• Lightweight Energy Source
  WaveSol™ Mobile high efficiency solar modules, created using thin-film PV technology, are up to 10 times more powerful than a conventional battery. Just one hour of direct sunlight will power 40 minutes of usage

$ASTI - DAILY CHART 

$AST SOLAR TECHNOLOGIES

Ascent Solar Technologies Announces Major Breakthrough in Solar Cell Performance for Space and Near-Space Environments

• ASTI recently announced a big breakthrough in the solar space, specifically in space and in near-space applications. In these applications, lightweight and high performance solar panels are very important. With that said, ASTI recently achieved a record 1,700 watts of power produced per kilogram of weight. As a result, future solar panels made for in space and near space applications can now weigh up to 60% less than conventional solar options for these applications!

Ascent Solar Technologies (ASTI) Modules Selected by Vanguard for NASA SBIR

• Ascent Solar Technologies (Nasdaq: ASTI) announced that its flexible, lightweight PV modules were selected by VanguardSpace Technologies (Vanguard) for their NASA Small Business Innovative Research (SBIR) program. The NASA program is intended to develop an economical, lightweight alternative to existing and emerging high-cost solar arrays for high-power space applications.

• Vanguard will utilize proprietary space environment protection technology along with automated manufacturing approaches to create an ultra-thin, high power-to-weight ratio, large space solar array. These arrays will be enabled by Ascent’s flexible copper-indium-gallium-selenium (CIGS) technology; Ascent will leverage their experience with space-based solar products to provide space-optimized variants of their production PV.

OTC: CYCA

CYTTA CORPORATION

Hot Medical / Tech Stock!

BIG POTENTIAL.  BIGGER PARTNERS.

I would like to introduce you to Cytta Corp. (OTC:PINK: CYCA).  Cytta is a micro-cap penny stock at about 4 cents per share, with big potential and even bigger partners.  CYCA has now developed three digitally disruptive technologies, VeriSmartPhone™, SUPER™ Compression and Wi-VHFi™ broadband.  Utilizing its VeriSmartPhone™ technology CYCA has built the Doctor Direct telehealth system which they utilize for collecting medical information from home healthcare monitoring equipment.  The information is passed from the home monitoring equipment to a specially programmed mobile phone.  The VeriSmartPhone™ then transmits the information to a central database in the Cloud where it is stored and reported to healthcare providers.  The database monitors the results utilizing artificial intelligence, immediately notifying the patient’s doctor when the upper or lower limits are violated.  Others can provide similar functionality in a less direct fashion.  CYCA has the technology and licenses to offer this technology directly through any smartphone.  No app is necessary.  The Cytta instruction set can never be accidentally disabled making Cytta’s technology ideal for an older and/or sicker patient base.  The same VeriSmartPhone™ technology can also be used to monitor and report data coming from any sensors including pipelines, transportation systems, and inventory systems.  CYCA’s big partners include Oracle who recently agreed to partner with Cytta in engineering Cytta’s technology for large scale usage.

WHAT DOES ORACLE SEE IN CYCA?

·         Since Medicare and Medicaid began allowing doctors to bill for remote monitoring, there is now a funding source for this technology.

·         There is no industry standard for the data collection, storage and reporting.  Oracle sees Cytta as its last mile solution in creating a new industry standard.

·         As valuable as the medical results are to individual patients, the ‘big data’ possibilities in years to come could prove invaluable to medical care on a global basis.  Oracle’s role as the database and reporting provider offers some very interesting long term opportunities.

Next Phase

•             Oracle grew to where it is today through smart deals with long term growth.  The Oracle deal makes CYCA look like a valuable prospect to other giants.  Cytta and Oracle are currently in rollout discussions with a major cellular Carrier.

Growth in home Health Care

•             Professionals and investors in the health care services industry are optimistic about the industry’s performance _ and they’re particularly bullish about the growth of the home health and hospice sector in the coming year.

CYTTA CORP.

6490 West Desert Inn Rd.

Las Vegas, NV  89146

Stock Symbol: CYCA

http://www.cytta.com/

Brought to you by FrontpageStocks.com

http://www.frontpagestocks.com/cytta-corp/

https://www.facebook.com/PennystockSCA/

The founders of INND decided to go public to facilitate its aggressive expansion plan in an industry expected to double over the next 10 years!

STOCK SYMBOL: INND

Innerscope Advertising Agency, Inc.

DECADES OF EXPERIENCE – PROVEN RESULTS

INND is a marketing and advertising agency, dedicated to serving the hearing aid dispensing community. Generating traffic and excitement through the client’s front door is what INND does best. Whether the practice is medium or large, INND can increase the total revenue without increasing cost. INND provides consulting services including store set-up, customer relations management and sales techniques, all to take advantage of the customers acquired in the course of the advertising and marketing campaigns.

INND’s “alliance” program enables independent hearing aid practitioners to leverage their collective purchasing power of hearing devices by grouping together and aggregating their purchases. INND plans to become a leader in auditory rehab training utilizing their interactive computer-based software program called Aware™, a self-assessment and training module that helps individuals work through simple to difficult auditory skills. INND is dedicated to serving the retail hearing aid dispensing community and developing a program to contribute to various hearing aid focused charities.

The founders of INND have decades of hands on experience and have built some of the largest hearing aid retail operations in the US. INND decided to go public to facilitate its aggressive expansion plan in an industry expected to double over the next ten years.

There are over 14,000 retail hearing aid dispensing practices in the United States. INND revenue streams of the company have expanded to include:

· Advertising and marketing service based on proven, proprietary models.

· Clinic design services that are unique to the industry, including Clinic set-up, customer relations management and sales techniques

· Expansion of their core ‘cooperative buying group’ enabling independent hearing aid practitioners to leverage their collective purchasing power of hearing devices by aggregating their purchases

· Become a leader in the auditory rehab market utilizing interactive web and mobile based self-assessment and training modules.


Advertising & Marketing

· INND designs and implements all the advertising and marketing activities for the client for the pre-determined demographic.

Customer Relationship Management (CRM)

· INND works with clients to help identify and market to their customer database, using automatic triggers to market to them.

Public Relations

· INND works with local and national press release companies to help the client write and publish press releases.

Specialty Communications

· INND excels in specialty communications by reaching each intended audience with communication styles & vehicles relevant to the targeted audience.


Innerscope Advertising Agency, Inc.
2281 Lava Ridge Court
Suite 130
Roseville, CA 95661
info@INND.com

info@innerscopeagency.com
www.INND.com
www.innerscopeagency.com

http://www.frontpagestocks.com/innerscope-advertising-agency-inc-innd/
http://badassstocks.com/innerscope-advertising-agency-innd/

Worthy of a look and a lot more, INCC has officially launched its website and ecommerce store @ http://BluDogProducts.com   

STOCK SYMBOL: INCC

International Consolidated Companies, Inc.

ABOUT INTERNATIONAL CONSOLIDATED COMPANIES, INC.

International Consolidated Companies, Inc. (OTC: INCC) is focused on acquiring and expanding global businesses that offer services and technologies to assist medical marijuana growers and patients.  INCC will provide or arrange for venture capital funding on qualified projects in the expanding legal cannabis industry through targeted acquisitions, brand recognition plus real-estate and technology joint ventures.  INCC believes it can capture significant market share in Colorado, Washington State, and California.  Working with a team of experienced growers and financial experts, INCC will evaluate small and large business opportunities.  INCC will provide both technology and consulting services to medical cannabis growers, activists and industry professionals.  Through perpetual rental agreements, the company offers growers’ state of the art turnkey solutions to improve efficiency, efficacy, and increase yield.  INCC believes it will generate revenue by renting its propriety technologies to qualified licensed medical growers; and by providing training and consulting services to assist lessees in operating their businesses more profitably.

BLUDOG PRODUCTS

BluDog Products, a subsidiary of INCC, is strategically introducing water-soluble CBD oil super food and wellness drinks (with an extended release formulation) that are easily absorbed.  Using a licensed and patented CBD delivery system, BluDog’s CBD products are an alternative over-the-counter therapeutic option to help relieve post-sports inflammation as well as promote relaxation and well-being.  BluDogs’s CBD products interact naturally with the body’s anti-inflammatory system without any known side effects.

Recent Developments

·         INCC recently announced it has selected Colorado based Premiere Elevations to license the St James Remedies brand for distribution in the Colorado state legal recreational marijuana market.

·         INCC recently announced it entered into an exclusive license agreement with CBD Medicinal, LLC for a patent application and trade secrets surrounding the development of an over-the-counter cannabidiol (CBD) formulation to improve cognitive function in adults.

·         INCC recently entered into an exclusive license agreement with Brooks Kelly Research, LLC for a patent portfolio covering formulated CBD beverages.

BluDog Product Information

·         BluDog Products, a subsidiary of INCC, develops premium organic CBD oil popsicles with Pop Craft™, a frozen confections company based in Sarasota, Florida.

·         BluDog Products will deploy highly effective marketing strategies to enter into the pain management category. The multi-billion dollar market for nutritional supplements continues to fuel growth potential in the healthcare, pharmaceutical and nutritional supplement industries. Industry analysts expect the nutrition supplement market to reach $175 billion globally by 2020.

·         BluDog Product’s patented proprietary HempCHOICE® (PCR) hemp oil extracts which deliver a full spectrum of cannabinoids and terpenes. We use the patented VESIsorb® delivery system making the full spectrum of cannabinoids and terpenes including CBD “body ready” for improved absorption bioavailability and maximum benefits.

·         No other provider has BluDog Product’s exclusive formulation for maximum absorption.  PCR is extracted from pesticide-free hemp, is glycerin, gluten and corn syrup free, has no added sugar, and is non-GMO. All products are tested by a third-party lab for purity ensuring the highest quality PCR products.

International Consolidated Companies, Inc.

8191 North Tamiami Trail

Sarasota, FL 34243

Baltic38dp@me.com

https://www.bludogproducts.com/

http://www.frontpagestocks.com/international-consolidated-companies-inc-incc/

http://badassstocks.com/stock-alert-international-consolidated-companies-inc-incc/

Vapetek, Inc. (OTC:VPTK) is a technology company engaged in developing, marketing and selling electronic cigarettes (“e-cig”), e-liquids, rechargeable batteries and vapor devices in the emerging growth e-cigarette industry.

STOCK SYMBOL: VPTK

Vapetek, Inc.

WELCOME TO VAPETEK

VPTK is a publicly traded technology company engaged in developing, marketing, and selling electronic cigarettes and or “Vapor”, E-liquids, vape supply, rechargeable vape mods, and vape devices in the emerging e-cigarette industry. All of VPTK products are U.S. pharmacopeia (USP) grade which means their e-liquids meet the product quality and standards set by the United States Pharmacopeial Convention, a non-profit organization that publishes food ingredients and dietary supplements. VPTK has positioned itself as a technology company focused on the adoption of electronic vaporizing cigarettes (commonly known as “e-cigarettes) by the world’s 1.2 billion smokers. VPTK provides high quality e-cigarette devices, electronic refillable and rechargeable atomizers and e-liquids offering a much safer alternative delivery system for nicotine.

VAPEBIT SMART CONTRACTS

VapeBIT Blockchain (VBT) is a ground breaking peer-to-peer payment solution for banks, merchant processors, vape industry (Vaporizers, E-Cigarettes, and other Electronic Nicotine Delivery Systems) and the alternative products industry. The protocol is built upon a distributed open source internet protocol, proof-of-stake (POS) consensus ledger and native currency. VapeBIT enables cross-border payments without the need of correspondents, capable of transfer speeds of 30 seconds or less. VapeBIT is an asset exchange smart contract token designed for the vape and alternative products industry that uses a proven industrial performance and scalable platform that doesn’t rely on the traditional routes or ICANN. VapeBIT operates smart contract applications that run exactly as programmed without any possibility of downtime, censorship, fraud or third party interference, without a middle man or counterparty risk.

The e-cig Market

· A report by Research and Markets forecasts that the global e-cigarette market will grow at a CAGR of 24.33% during the period 2016-2020.

· Analyst Bonnie Herzog of Wells Fargo Securities estimated $4.4 billion in vapor product sales in the US in 2017. By 2019, the industry is expected to grow by 20% to 118.6 billion.

VapeBIT Model

· VapeBIT total supply: 77.5M

· 60% has been allocated for the ICO 46,500,000 is being sold during the ICO.

· VPTK will retain 20% of the total Circulating Supply of VapeBIT or 15,500,000.

· 3% Will Be Distributed to the Vape Community and industry Partners or 2,325,000

· The founders of Vapetek, Inc. hold 17% or 13,175,000.

Vapetek, Inc.

580 West Cheyenne Ave.

Suite 160

North Las Vegas, NV 89030

www.vapetek.com

http://www.frontpagestocks.com/vapetek-inc-vptk/

http://badassstocks.com/stock-alert-vapetek-inc-vptk/

RGBP is focused on the immunology and immunotherapy space. The Company plans to rapidly advance novel technologies through pre-clinical and Phase I/ II clinical trials as investors look to expand portfolios.

STOCK SYMBOL: RGBP

Regen Biopharma, Inc.

ABOUT REGEN BIOPHARMA, INC.

Regen Biopharma, Inc. (OTCQB: RGBP) is a biotechnology company focused on stem cell and immunotherapies for specialty niche treatments. This includes identifying undervalued regenerative medicine applications in the stem cell/immunotherapy space and rapidly advancing these technologies through pre-clinical and Phase I/II clinical trials. Currently RGBP is developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with immunotherapy (dCellVax), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate). RGBP is a biotechnology company focused on stem cell and immunotherapies for specialty niche treatments.

PRODUCT PIPELINE - REGEN BIOPHARMA, INC.

RGBP has identified and filed patents on small molecules that activate and inhibit a novel gene (NR2F6) which controls how the immune system reacts to cancer cells and to inflammatory responses.

HemaXellerate is a personalized cellular therapeutic product designed to stimulate blood production in patients whose bone marrow is not properly functioning. (HemaXellerate IS CLEARED TO PROCEED TO PHASE I/II CLINICAL TRIALS)

CellVax is a dendritic cell based immunotherapy that stimulates the patient’s immune system through a process called “gene silencing”.

DiffronC is a novel form of therapy called differentiation therapy that is expected to have much milder toxicity than chemotherapy. The mechanism of action is to correct the specific genes that prevent the myelodysplastic syndrome stem cell from producing mature blood cells.

RECENT DEVELOPMENTS

· RGBP sees additional positive results on its medicinal chemistry optimization for modulating NR2F6 checkpoint for treating cancer and autoimmune diseases.

· RGBP in conjunction with its medicinal chemistry partner, ChemDiv, Inc., has identified three new series of compounds that activate NRF26.

· RGBP completed the first phase of its small molecule optimization program, which involved synthesizing more than 40 analogues of its initial lead compounds (RG-NA01, RG-NA02, RG-NI01 and RG-NI02).

· RGBP announced that its management team has agreed to collectively cancel 16,500,000 common shares and 15,000,000 Series A Preferred shares.

RECENT PRESS RELEASES

· Regen BioPharma, Inc. Addresses Potential Impact of Recent Bristol Myers Squibb's $2.3 Billion Acquisition of IFM Therapeutics. Regen BioPharma Inc. (RGBP) and (RGBPP) sees recent deal activity in the immune oncology space as an indication that big pharma continues to place significant bets on the ability of biotech companies to create the innovation they seek. https://finance.yahoo.com/news/regen-biopharma-inc-addresses-potential-110000864.html

· Regen BioPharma, Inc. Research Demonstrates Ex-Vivo Immune Suppression With Novel NR2F6 Activators. Regen BioPharma Inc. (RGBP) and (RGBPP) today reported continued progress in Regen's development of small molecule drugs that activate and inhibit NR2F6. https://finance.yahoo.com/news/regen-biopharma-inc-research-demonstrates-120000740.html

· Regen BioPharma, Inc. Researchers Discover New Dynamic Compound Which Modulates the NR2F6 Checkpoint. Regen BioPharma Inc. (RGBP) and (RGBPP), today reported continued progress in developing small molecule drugs that activate and inhibit NR2F6. The Company reports that using a focused compound library and Regen's patented screening methodology; it has identified a dynamic new chemical compound series that modulates NR2F6. https://finance.yahoo.com/news/regen-biopharma-inc-researchers-discover-120000579.html

· Regen BioPharma, Inc. Sees Additional Positive Results on its Medicinal Chemistry Optimization for Modulating NR2F6 Checkpoint for Treating Cancer and Autoimmune Diseases. Regen BioPharma Inc. (RGBP) and (RGBPP) states that progress continues to be achieved by Regen in developing small molecule drugs that activate and inhibit NR2F6. The Company reports that ChemDiv, Inc., Regen's medicinal chemistry partner, has currently identified three series of compounds which activate NR2F6. Regen is working towards small molecule therapies that can treat cancer as well as autoimmune disorders such as arthritis and lupus. https://finance.yahoo.com/news/regen-biopharma-inc-sees-additional-120000036.html

Regen Biopharma, Inc.

4700 Spring Street

Suite 304

La Mesa, CA 91942

David.koos@regenbiopharma.com

www.regenbiopharmainc.com

http://www.frontpagestocks.com/regen-biopharma-inc-rgbp/

http://badassstocks.com/stock-alert-regen-biopharma-rgbp/

Global Payout Inc. has invested with promising success in developing and implementing a Consolidated Payment Gateway (CPG) allowing enterprise clients to provide direct bank account, mobile account, and prepaid card account options within compliance, a much needed service in the Cannabis industry.

STOCK SYMBOL: GOHE

Global Payout, Inc.

ABOUT GLOBAL PAYOUT, INC.

Headquartered in San Diego, GOHE is a Public Company providing comprehensive account, car and payment solutions for domestic and international organizations, including private banking account solutions for its recent acquisition of ISBC Holdings Limited.  ISBC Holdings Ltd. Is the sole manager for International Sovereign Banking Corporation (“ISBC”); a new, Native American owned Sovereign banking institution (in formation) that has plans to offer new and evolved cloud banking services and product solutions to domestic and international customers. GOHE, through its acquisition of ISBC Holdings, Ltd. will be designing and operating the cloud banking platform interface, including all technical and back office functionality behind the ISBC private banking account and product.

HOW BLOCKCHAINS BENEFIT FINANCIAL SERVICES

GOHE ‘s new launch into the FINTECH industry offers individuals, enterprises and governments the opportunity to allow anyone, anywhere to buy  and convert any form of currency or commodity inexpensively compared to the commercial banking industry. GOHE believes that the world’s population is denied access to affordable banking and wants to eliminate expensive currency exchanges and account maintenance fees traditionally charged by banks.  GOHE is in the beginning stages of developing a new financial ecosystem that is confident will benefit individuals, companies and governments in all countries of the world.

Recent Developments

·         GOHE recently completed a joint venture agreement with Compliance Financial Network Corp. (CFN), an innovative compliance technology and cash logistics company.  The Company contends these features will aid in the ability to more effectively manage and mitigate risk as well as comply with all federal, state and county level regulatory requirements.  https://finance.yahoo.com/news/global-payouts-majority-owned-subsidiary-104500355.html?soc_src=social-sh&soc_trk=tw

·         GOHE announced it has finalized a Customized Licensing Agreement for the use and exclusive white labeling of its Global Reserve Platform with companies Trade & Service LTD (“CTS”), a London based VAT Recovery and FOREX processing service provider.  http://finance.yahoo.com/news/global-payout-inc-bolsters-suite-104500677.html?soc_src=hl-viewer&soc_trk=tw

·         GOHE announced that its majority owned subsidiary, MoneyTrac Technology, Inc., completed a Letter of Intent and business development relationship with PotSaver™, a Southern California based community periodical providing listings on discounted cannabis-related products for local dispensaries and shops.  https://finance.yahoo.com/news/global-payout-announces-majority-owned-104500651.html

·         GOHE announced it received an investment of $250,000 in exchange for 15% of MoneyTrac Technology, Inc. (“MTT”), its subsidiary, by Marijuana Company of America (OTC: MCOA)

MCOA made this investment to help establish and market MTT as an alternative banking solution for the cannabis industry.  MoneyTrac ™ software has the ability to integrate and streamline electronic payment processing, such as E-Wallet and mobile applications, as well as manage and process prepaid cards, debit cards, and credit card payments. https://finance.yahoo.com/news/marijuana-company-america-completes-250-113000968.html

·         Global Payout, Inc. and MoneyTrac Technology Enter the Multi-Billion Dollar CBD Market through their Agreement with H Smart, Inc. for the use of MTRAC's financial technology platform. The technology available in MTRAC's platform, via software developed and provided by Virtu Network Solutions, will be utilized by H Smart for payment of commissions to H Smart's affiliates. GOHE projects that these load payments and bank account transfers will generate substantial revenue to MTRAC that will be realized this fiscal quarter. https://finance.yahoo.com/news/global-payout-inc-moneytrac-technology-123000600.html

Global Payout, Inc.

1835 Sunset Cliffs Blvd

Suite 202

San Diego, CA  92107

information@globalpayout.com

www.globalpayout.com

http://www.frontpagestocks.com/global-payout-inc-gohe-2/

http://badassstocks.com/stock-alert-global-payout-gohe/

ECOB is a manufacturer of environmentally responsible technology within it's products that protect against fire, mold/mycotoxins, fungus, rot-decay, wood ingesting insects and termites. First Q of positive EBITDA just announced.

ECO RED SHIELD - PROVEN CHEMISTRY AND TECHNOLOGY

Eco Building Products, Inc.

OTC TRADING SYMBOL – ECOB

ABOUT ECO BUILDING PRODUCTS

Headquartered in San Diego, CA, Eco Building Products, Inc. ECOB is a manufacturer of proprietary, environmentally conscientious chemistry utilizing patent pending ECOB WoodSurfaceFilm and FRC technology (Fire Retardant Coating).  ECOB wood coatings are typically applied to wide range of lumber products.  ECOB ’s proprietary eco-friendly formula controls moisture and protects lumber from mold, mildew, fungus, decay, rot, termites and other wood boring insects including Formosan termites, while simultaneously serving as a fire inhibitor.  ECOB ’s formulas have protected hundreds of wood structures and hundreds of millions of board feet of lumber without a single claim.

Eco Building Products, Inc., or ECOB, has developed a line of eco-friendly protective wood coatings, Eco Red Shield ™ and Eco Clear Shield ™, which extend the lifecycle of framing lumber and other wood products used in the construction of single-family homes and multi-story buildings.  The Company has changed its product offering breaking up the wood treatment into three different categories to include Eco Red Shield Sill Plate, Eco Red Shield Advanced Framing Lumber and Eco Red Shield Fire Treated.

Superior Product

·         Eco-friendly coatings that remain chemically stable over time

·         Emits zero volatile organic compounds (VOCs)

·         Does not leech heavy metals or toxins into groundwater

·         Does not allow for the growth and propagation of various molds on the cured film surface

·         Provides better  indoor air quality

Recent Developments

·         Secured a $400,000 credit facility to fund the Company’s launch and immediate term ramp up.

·         Entered into discussions with potential joint venture partners as well as potential exclusive licenses for Eco D-Fence™ and Eco Red Shield™ line of products.

Press Releases

·         Eco Building Products, Inc. Subsidiary, Wood Protection Technologies (WPT), Hires New Director of Chemistry and Technology on August 3, 2017 it was announced Dr. Jinxue Jiang will become the Company’s new Director of Chemistry and Technology.

https://ecob.net/2017/08/03/eco-building-products-inc-subsidiary-wood-protection-technologies-wpt-hires-new-director-of-chemistry-and-technology/

·         Eco Building Products, Inc. Releases Marketing Update July 28, 2017

The Company reports new direct sales efforts as well as new social media marketing

https://ecob.net/2017/07/28/eco-building-products-inc-releases-marketing-update/

·         Eco Building Products, Inc. Announces That the Company’s Subsidiary, Wood Protection   Technologies (WPT), Delivered Positive EBITDA in May  WPT revenues have exceeded forecast while gross margin meet expectations

https://ecob.net/2017/07/13/eco-building-products-inc-announces-that-the-companys-              subsidiary-wood-protection-technologies-wpt-delivered-positive-ebitda-in-may-2/

        

Eco Building Products, Inc.

11568 Sorrento Valley Road

San Diego, CA 92121

info@ecob.net

www.ecob.net

http://www.frontpagestocks.com/eco-building-products-inc-ecob/

http://badassstocks.com/eco-building-products-inc-ecob/

ENTB is developing veterinary treatments for cancer and autoimmune disorders in Dogs, Cats and animals!

STOCK SYMBOL: ENTB

Entest Biomedical, Inc.

SPECIALIZING IN CUTTING EDGE THERAPIES FOR ANIMALS

Zander Therapeutics, Inc. is a veterinary biotechnology company that is wholly owned by ENTB.  Zander is focused on developing veterinary treatments for cancer and auto immune disorders (such as arthritis) by enlisting the animals’ own immune system.  Zander’s main areas of interest include: autoimmune disorders such as arthritis, immunotherapies for cancer treatment in canines and bone marrow suppression therapy for animals treated with chemotherapy and radiation therapy.  ENTB is targeting canine cancer, especially considering that 50% of all dogs over the age of 10 years will develop some form of cancer. Feline Leukemia (FL) is another focal point, with 2-3% of all cats in the United States carrying the feline leukemia virus.  Additionally, ENTB is looking at arthritis in animals from dogs and cats to thoroughbred horses.

ENTB’s goal is to utilize small molecule therapies for treating autoimmune disorders (arthritis) in animal companions, feline leukemia (cats) and canine cancer (dogs).  Currently, Zander Therapeutics is developing products treating blood disorders using small molecules based on nuclear receptor NR2F6 under an exclusive license agreement for veterinary use from Regen BioPharma Inc. (OTCQB: RGBP).  Ongoing objectives include gene silencing for treating cancer with immunotherapy, modulating key molecular processes in cancer stem cells through Zander’s patented molecular targeting approaches and repairing damaged bone marrow in animals with aplastic anemia and bone marrow suppression due to side effects of chemotherapy and radiotherapy-treated cancer patients.

Products in Development

·         ZT 110 is an NR2F6 inhibitor feline leukemia

·         ZT 240 is an NR2F6 inhibitor for canine cancer

·         ZT 396 is an NR2F6 stimulator for exercise included pulmonary hemorrhage (equine)

Dogs in the United States

·         A 2015-16 survey from the American Pet Products Association found the number of pet dogs in the U.S. to be approximately 77.8 million

Cats in the United States

·         A 2015-16 survey from the American Pet Products Association (APPA) found the number of pet cats in the U.S. to be approximately 85.8 million

Entest Biomedical, Inc.

4700 Spring Street

Suite 304

La Mesa, CA 91942

venturebridge@gmail.com

www.zandertherapeutics.com

http://www.frontpagestocks.com/entest-biomedical-inc-entb/

http://badassstocks.com/stock-alert-entest-biomedical-entb/